← All trials
NCT05683184
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2023
- Primary completion
- Dec 15, 2025
- Completion date
- Dec 15, 2025
- First posted
- Jan 13, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- Yale UniversityOverall official - principal investigator
- Yale UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.